CLNN CLNN
Company Profile ↓Company Overview
CLNN (CLNN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 148.8%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $200.00K (-41.5% YoY); net profit $-26.17M.
- Trailing 12 Months Year-on-year growth — revenue -41.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.59% |
| 1 Year: | -41.52% |
Stock Price Performance
| 1 Year: | +43.85% |
| 6 Months: | +26.00% |
| 3 Months: | -18.24% |
| 1 Month: | -12.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.43 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 148.8%.
CONS
- Revenue declined at -0.6% CAGR over 5 years.
- Trading 57.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.00K | 9.00K | 98.00K | 213.00K | 201.00K | 110.00K | 30.00K | 35.00K | 174.00K | 107.00K | 269.00K | 108.00K | 73.00K | 91.00K | 87.00K | 81.00K | 27.00K | 15.00K | 15.00K |
| Operating Income | -4.00M | -4.56M | -5.69M | -11.70M | -13.78M | -10.45M | -13.34M | -13.60M | -9.80M | -10.73M | -10.34M | -9.54M | -9.23M | -7.39M | -7.82M | -4.08M | -5.86M | -5.65M | -2.06M |
| Net Income | -3.94M | -5.82M | -10.29M | -39.76M | -3.35M | 28.94M | -13.35M | -4.53M | -10.98M | -11.77M | -25.14M | -2.42M | -11.08M | -6.79M | -7.99M | -751.00K | -7.42M | -8.78M | -8.09M |
| Diluted EPS | - | - | -0.59 | - | -0.05 | 0.42 | - | -0.07 | -0.17 | - | - | - | - | - | - | - | - | - | - |
| R&D Expense | 3.20M | 3.55M | 3.99M | 6.28M | 6.47M | 6.15M | 8.58M | 9.17M | 6.40M | 7.39M | 6.62M | 5.97M | 5.87M | 4.15M | 4.47M | 1.48M | 3.51M | 3.51M | 329.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 206.00K | 723.00K | 473.00K | 654.00K | 342.00K | 200.00K |
| Operating Income | -16.33M | -20.21M | -49.98M | -48.41M | -40.54M | -33.09M | -23.08M |
| Net Income | -16.16M | -19.28M | -9.74M | -29.92M | -49.50M | -39.40M | -26.17M |
| R&D Expense | 9.56M | 15.20M | 28.42M | 31.92M | 26.66M | 20.06M | 14.01M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 14.88M | 68.24M | 63.06M | 44.49M | 52.34M | 27.34M | 18.13M |
| Total Equity | -52.04M | -67.77M | 341.00K | 12.60M | 3.24M | 13.39M | -8.86M | -17.59M |
| Cash & Equivalents | - | 8.79M | 59.27M | 50.29M | 18.33M | 28.82M | 12.15M | 5.19M |
| Long Term Debt | - | - | - | - | - | - | - | 17.79M |
| Total Liabilities | - | 9.99M | 67.90M | 50.47M | 41.26M | 38.95M | 36.19M | 35.72M |
| Current Liabilities | - | 4.31M | 11.67M | 6.03M | 13.86M | 25.33M | 10.29M | 10.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.20M | -18.93M | -34.62M | -39.01M | -30.17M | -21.33M | -18.55M |
| Investing Cash Flow | -294.00K | -387.00K | -1.33M | -10.16M | -1.50M | 6.32M | -39.00K |
| Financing Cash Flow | 5.50M | 69.53M | 27.11M | 17.25M | 42.16M | -1.53M | 11.52M |
| Capital Expenditure | -294.00K | -387.00K | -1.33M | -5.18M | -330.00K | -15.00K | -39.00K |
| Free Cash Flow | -13.49M | -19.32M | -35.96M | -44.19M | -30.50M | -21.34M | -18.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | -9,812.6% | -6,912.6% | -10,234.5% | -6,198.8% | -9,676.3% | -11,541.5% |
| Net Margin % | - | -9,357.8% | -1,347.2% | -6,325.2% | -7,569.4% | -11,520.5% | -13,086.5% |
| ROE % | 23.8% | -5,653.1% | -77.3% | -924.3% | -369.7% | 444.8% | 148.8% |
| ROCE % | -154.6% | -35.7% | -87.6% | -158.0% | -150.1% | -194.1% | -313.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLNN
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNay1lYXdYRTN4ODVjN2pmdnZnRDZKU1lIRTExZ1lwRDNqTU5BZ2JJNFZ2akliM1pLS0FTdHFVOUc2Ry1oWFdJNmZ6eTFVQzlzZXBuN3BlMFNhNWlSbDRCWDRldXkwdXFKcjRwT2NkeThPVVFyMzVFRjl5NFR2cjFMTkpzbWJyeGdwTUhtbW…
Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPMFR5MXROXzRDSHNZSkxfRXhCNlF0MjQzdzRXWUVUWDhlR1BvOE1mdzctYkxuY0hxZEdYaGJrd28tQWk5VlZWNmtEemR0QXNGU3dWY0gxdlFOaEVYSVppcU14TzZYNFVkSTFxbUl5UHl3eWhuUUw5Rl9RZTVKSkIzRmlwQ25pelZwZHVtNk…
Empery Asset Management (CLNN) discloses 7.17% beneficial stake in Clene - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQOThSclIyTUFkSXZodjNGOGhvcmxSUUs0VG90Y1gxTFlYRGZmUGxkMHZDQzlyczBLUy02MEc1aHVOOEJ0OGhDV2pZY2hEQVl6dmMwVkhDeHhXbUZiYld6R3pFTk45aG53SFlULXQ2RVo3SE5WRUZ3LTkwMU9jeHdQOHRkQXRqU3BPTnN5UG…
CLNN Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFB5eXE0Ti1XVUVidzgyR2h6SXBwRWhxNWFUU2hMN0haOUpIVU5rSUdBcExhX1lLUDNHc05EM3FiT3BfRVZHVU9melN3Qms4TWdyWUJzWGVPYVBUX0NfaUFwMXpsZGV0ODh6MEZ0RWgyWGE2SWV5aVI2SW1B?oc=5" target="_blank">CLN…
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPbm9LTGVWR3h5MER4UGc3QW1hdUYtd1lxaXZMbWR6SURrNlBreXp6anJmdl90VDZ3YlhWX3hHZERBTXlaRTFsM09HaXFCZnNxMjFyRUt2c2Y1M0JGZW0zZ2VRRmh4cGx3QTloWjZxREU5dFQxVTBVU3U4dFVTTS00eFZkNjY4bkZBZzEwVD…
Clene Inc. (CLNN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBUWWdUN1ZxWkdPc2k4bkhpNWxPU2cyNjdhMkdDcTlIaURIOUJmT29DWWVpYjJqU2RuUTJkZkQzRzBKVGxlUnpWREFCQ1BIMVFBVzdCcnBCaWRqRXJDcHV2VTFDZDIzZw?oc=5" target="_blank">Clene Inc. (CLNN) Earnings Fo…
CLNN — Frequently Asked Questions
What is the current share price of CLNN?
As of 2026-08-05 17:25 PDT, CLNN trades at $5.38 on NASDAQ/NYSE. Its 52-week range is $3.60 to $12.50.
What is the return on equity (ROE) of CLNN?
CLNN has a return on equity (ROE) of 148.78%.
Is CLNN a good stock to buy?
This page provides a data-driven analysis of CLNN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.